Because their platform generates more high-potential drug targets than they can pursue internally, the company frames partnerships with large pharmaceutical firms as an ethical imperative. This approach ensures novel findings don't languish, allowing them to become life-saving drugs while triggering revenue sharing for their community partners.

Decentralized Autonomous Organizations (DAOs) can shift the power dynamic in large partner ecosystems. Instead of a top-down vendor model, partners can collectively propose, vote on, and update incentive rules. This transforms partners from being passive recipients of policy into active co-creators, fostering a more collaborative and competitive "living ecosystem."

Variant Bio's advantage lies in its ethical approach to partnering with indigenous communities. This model, which includes co-designing studies and robust benefit sharing, grants them exclusive access to unique genetic datasets that competitors, focused on traditional data sources, cannot obtain.

Luba Greenwood reframes competition in biotech as a positive force. When multiple companies pursue the same biological target, it validates the target's importance and accelerates discovery. This collaborative mindset benefits the entire field and, ultimately, patients, as the best and safest drug will prevail.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

To avoid undue influence, individual participants are not paid cash. They receive immediate value via their own health test results. The significant financial upside, including 4% of revenue and equity, is reserved for the community as a whole, creating a sophisticated, multi-layered ethical compensation framework.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Structuring compensation around a single, firm-wide P&L, rather than individual deal performance, eliminates internal competition. It forces a culture of true collaboration, as everyone's success is tied together. The system is maintained as a meritocracy by removing underperformers from the 'boat.'

Benchmark's unconventional structure, where all partners have equal equity and power, aligns incentives for collaboration. Instead of the 'sharp elbow' culture of hierarchical firms, this model ensures senior partners are motivated to mentor and support junior members, as everyone shares equally in their success.